Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPodiatryAetna Hammertoe Repair Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0636

    Hammertoe Repair

    Customize your policy alerts

    Sign up for Aetna Policy 0636 alerts

    Get alerted when Policy 0636 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage criteria and coding for surgical repair of hammertoe (including claw and mallet toe) in skeletally mature individuals, and evaluation of fixation implants. Applies to Aetna plan members and providers submitting claims to Aetna.

    Policy Summary
    PayerAetna
    PolicyHammertoe Repair
    Policy CodePolicy 0636
    Change TypeNo material change
    Effective DateAug 16, 2002
    Last ReviewSep 13, 2023
    Next Review DateJul 11, 2024
    Key ActionDocument radiographic confirmation, skeletal maturity, and at least 3 months of conservative treatment before performing hammertoe surgery.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    >=3 months
    Conservative treatment duration
    85%Fusion rate (intramedullary)
    10.6%Smart Toe breakage (1 yr)
    640–894xImplant cost increase

    Coverage and Medical Necessity Criteria

    Medical necessity criteria

    Aetna considers hammertoe surgical repair medically necessary when ALL of the following are met:

    Primary requirements: Radiographic confirmation of hammertoe deformity with interpretation and report of anterior/posterior and lateral foot views; documentation of skeletal maturity (evidence of epiphyseal closure or age ≥ 18 years); and documentation of persistent pain and difficulty walking following at least 3 months of conservative treatment under the direction of a health care professionalall

    Conservative treatment includes, but is not limited to: corticosteroid injections; debridement of corns/calluses; foot orthotics or shoe modifications (may be contractually excluded); oral analgesics/NSAIDs; protective padding; and taping/adhesive devices.

    Indications for surgery (≥1 required): Member has one or more of the following: adventitious dorsal bursitis of the hammertoe; ankylosis of the DIP or PIP joint; inter-digital neuroma caused by the deformity; lateral MTP capsular tear caused by the deformity; painful nail conditions secondary to persistent trauma; presence of co-existing/causative conditions (e.g., tendon contracture) that need repair; subluxation or dislocation of the MTP joint; synovitis/capsulitis of the MTP joint; or ulceration of the apices.1_of

    At least one of these listed indications must be documented.

    Repeat procedures

    Repeat surgical treatment

    Repeat surgery: Repeat hammertoe surgical treatment is considered medically necessary following failure of a previous surgical procedure.all

    Documentation should support prior surgery and subsequent treatment failure.

    Implants considered experimental/investigational

    Experimental / investigational devices

    Implants considered experimental/investigational: Use of the following fixation implants for hammertoe repair is considered experimental and investigational due to lack of evidence of effectiveness and safety: Acumed Hammertoe Fusion Set; BME Hammerlock Implant; CannuLink Intramedullary Fusion Device; CrossTie Intraosseous Fixation System; Futura Flexible Digital Implant; Futura LMP Lesser Phalangeal Joint Implant; HammerFix IP Fusion System; Integra Hammertoe Implant; OsteoMed Interflex IPG System; Pro-Toe Hammertoe Implant; Smart Toe; StayFuse Fusion Device; ToeGrip Device; ToeTac Xpress hammertoe fixation system; Two-Step Hammer Toe Implant; Weil-Carver Hammertoe Implant; Wright Cann Phalinx System.any

    Use of these implants may render the procedure non-covered or experimental; documentation of use may affect coverage determination.

    Evidence and coverage considerations

    Summary of clinical evidence and inferred coverage implications

    Evidence summary: Multiple small observational studies, comparative retrospective reviews, and systematic reviews report that intramedullary/internal fixation devices can achieve fusion rates comparable to or slightly higher than percutaneous K-wire fixation, but they have not consistently demonstrated superior outcomes in pain, patient-reported function, or lower complication rates. Specific implants (e.g., Smart Toe) have been associated with higher hardware failure/breakage in some series. Formal cost-effectiveness analyses find commercial intramedullary implants minimally more effective but substantially more costly than K-wires, favoring K-wire fixation from a healthcare system perspective.

    References in the evidence include Basile et al. (2015), Obrador et al. (2018), Albright et al. (2018), Richman et al. (2017), Wei et al. (2020), Hendrick & Kannegieter (2020); empirical findings include reported fusion rates, implant breakage rates (e.g., Smart Toe ~10.6% within 1 year), and large unit-cost differences (K-wire £0.37 vs implant £236–£331).

    Use of the specific fixation implants listed in this policy (for example: Acumed Hammertoe Fusion Set; BME Hammerlock; CannuLink Intramedullary Fusion Device; CrossTie Intraosseous Fixation System; Futura Flexible Digital Implant and Futura LMP Lesser Phalangeal Joint Implant; HammerFix IP Fusion System; Integra Hammertoe Implant; OsteoMed Interflex IPG System; Pro-Toe Hammertoe Implant; Smart Toe; StayFuse Fusion Device; ToeGrip Device; ToeTac Xpress hammertoe fixation system; Two-Step Hammer Toe Implant; Weil-Carver Hammertoe Implant; Wright Cann Phalinx System) is considered experimental and investigational for hammertoe repair because of a lack of evidence of effectiveness and safety in the peer‑reviewed published medical literature.

    Routine use of higher‑cost commercial intramedullary implants in place of standard percutaneous K‑wire fixation is not supported without documentation justifying medical necessity or cost‑effectiveness. A formal cost‑effectiveness analysis found commercial implants to be only minimally more effective yet substantially more expensive (total cost per case reported as $6,059 for commercial implants vs $5,041 for K‑wire), producing an incremental cost‑effectiveness ratio that did not justify routine use of implants from a healthcare system perspective.

    Unit cost comparisons similarly demonstrate large cost differentials (example unit costs reported: K‑wire ~£0.37, ToeGrip ~£236.94, SmartToe ~£331), representing several hundred‑fold higher per‑unit costs for implants versus K‑wires and supporting the need for documented justification when selecting a commercial implant.

    Hammertoe surgical repair is considered experimental and investigational when the policy's stated medical necessity criteria are not met. In such cases, procedures using the listed fixation implants may be non‑covered because the required documentation and clinical indications (e.g., radiographic confirmation, skeletal maturity, failed conservative therapy) are not present.

    Given the available evidence showing similar clinical effectiveness between percutaneous K‑wire fixation and intramedullary implants but substantially higher costs for implants, routine selection of higher‑cost implants is not justified without clear clinical rationale. Providers choosing commercial intramedullary devices should be prepared to document why K‑wire fixation is unsuitable or why the implant is medically necessary for the individual patient.

    Procedure and Diagnosis Codes

    Covered CPT Codes (if selection criteria met)CPTCovered
    28285Correction, hammertoe (e.g., interphalangeal fusion, partial or total phalangectomy)
    28286Correction, cock-up fifth toe, with plastic skin closure (e.g., Ruiz- Mora type procedure)
    Other related CPT codesCPT
    11044-11047Debridement, bone (includes epidermis, dermis, subcutaneous tissue, muscle and/or fascia, if performed)
    73620-73630Radiologic examination, foot
    HCPCS codes not covered for indications listedHCPCSNot Covered
    L8641Metatarsal joint implant
    Other HCPCS / injectable codes referencedHCPCS
    J0702Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg
    J1020Injection, methylprednisolone acetate, 20 mg
    J3300Injection, triamcinolone acetonide, preservative free, 1 mg
    J3301Injection, triamcinolone acetonide, not otherwise specified, 10 mg
    L3000-L3030Foot, insert/plate, removable
    ICD-10 codes covered if selection criteria are metICD-10Covered
    E64.3Sequelae of rickets [hammertoe, claw toe, mallet toe]
    M20.40 - M20.42Other hammer toe(s) (acquired)
    M24.571 - M24.576Contracture of joint, ankle and foot [MP joint]
    S92.521x - S92.529xSprain of metatarsophalangeal joint of toe [lateral MP capsular tear]

    Provider Requirements, Documentation, and Authorization

    Prior Authorization

    Prior authorization / code coverage tied to policy criteria

    Select CPT and HCPCS codes listed in the policy are covered only when the policy's clinical selection criteria are met; certain fixation implants and specific HCPCS codes (for example, L8641 metatarsal joint implant) are identified as not covered for the indications in this bulletin.

    Prior Authorization

    Prior authorization advisable for commercial intramedullary implants

    When choosing higher‑cost commercial intramedullary implants instead of standard percutaneous K‑wire fixation, obtain prior authorization or be prepared to justify the clinical and cost rationale because commercial implants are substantially more costly and may not be supported without justification.

    Step Therapy

    Conservative care requirement — ≥3 months documented

    Clinical Background

    Hammertoe, claw toe, and mallet toe are deformities of the lesser toes (toes 2–5) characterized by abnormal flexion/extension contractures that may be flexible or rigid. Common causes include chronic tendon imbalance, trauma, neuromuscular disorders, and inflammatory arthropathies. Initial management is conservative (for example, orthotics, padding, debridement, injections); fixed deformities, persistent pain, functional impairment, or complications such as ulceration, bursitis, or ankylosis may necessitate surgical correction using procedures such as arthrodesis, arthroplasty, tendon transfers, or phalangectomy with fixation.

    Surgical stabilization for proximal interphalangeal (PIP) joint arthrodesis can be achieved with temporary percutaneous Kirschner (K) wires or with commercial intramedullary/internal fixation implants. The policy notes that evidence does not consistently demonstrate superior safety or functional outcomes for newer implantable devices compared with K‑wire fixation, and that some implants have been associated with hardware issues in published series.

    Terms and Device Definitions

    Hammertoe / Claw toe / Mallet toe — definitions and brief descriptors
    HammertoeAbnormal flexion posture at the proximal interphalangeal (PIP) joint of one or more lesser toes; may be flexible or rigid; commonly involves the second toe
    Claw toeDorsiflexion of the proximal phalanx at the metatarsophalangeal (MTP) joint with plantar flexion of the PIP and DIP joints, producing a claw-like appearance
    Mallet toeFlexion contracture of the distal interphalangeal (DIP) joint only
    Clinical featuresDeformities may cause pain, limit function and shoe wear; can produce hyperextension of MTP or pressure-related callus formation
    Skeletal maturity — evidence and age threshold
    Definition of skeletal maturityEvidence of epiphyseal closure or age 18 years or older
    Policy Summary
    PayerAetna
    PolicyHammertoe Repair
    Policy CodePolicy 0636
    Change TypeNo material change
    Effective DateAug 16, 2002
    Last ReviewSep 13, 2023
    Next Review DateJul 11, 2024
    Key ActionDocument radiographic confirmation, skeletal maturity, and at least 3 months of conservative treatment before performing hammertoe surgery.
    SourceLink
    On This Page
    Coverage and Medical Necessity CriteriaProcedure and Diagnosis CodesProvider Requirements, Documentation, and AuthorizationClinical BackgroundTerms and Device Definitions

    Document that the member has undergone at least 3 months of conservative treatment directed by a health care professional (examples below) prior to surgical repair; lack of such documentation may render the procedure non‑covered.

    • Corticosteroid injections
    • Debridement of corns/calluses
    • Foot orthotics or shoe modifications (may be contractually excluded)
    • Oral analgesics/NSAIDs
    • Protective padding; taping or adhesive devices
    Step Therapy

    Step‑therapy preference: try K‑wire fixation first

    Consider percutaneous K‑wire fixation as the first‑line surgical fixation option, as cost‑effectiveness analyses favor K‑wires (lower cost with similar effectiveness); document rationale if selecting a commercial intramedullary implant instead.

    • Albright et al. cost analysis: K‑wire total cost $5,041 vs commercial implant $6,059 and incremental cost‑effectiveness ratio unfavorable for implants
    Documentation Required

    Required documentation: radiographs, skeletal maturity, conservative care

    Include radiographic confirmation with interpretation and report of anterior/posterior and lateral views of the affected foot, documentation of skeletal maturity (evidence of epiphyseal closure or age ≥18), and records showing at least 3 months of conservative treatment and current indications for surgery.

    • AP and lateral foot radiographs with formal report
    • Evidence of epiphyseal closure or age ≥18 documented
    • Records of conservative treatments and duration (≥3 months)
    Documentation Required

    Suggested documentation to support device choice and outcomes

    Suggested clinical documentation to support medical necessity includes the specific indication for PIP joint arthrodesis, the type of fixation device planned or used (K‑wire vs named intramedullary implant), pre‑ and post‑operative pain and function scores, and any complications or comorbidities.

    • Indication for PIP joint arthrodesis (e.g., ankylosis, ulceration, painful nail condition)
    • Type of fixation device (K‑wire or specific intramedullary implant name)
    • Pre‑ and post‑op VAS/AOFAS or other function/pain scores
    • Complications and comorbid conditions
    Denial Risk

    Denial triggers — missing required documentation or experimental implants

    Claims may be denied if required items are missing: radiographic confirmation (AP and lateral views with report), documentation of skeletal maturity or age ≥18, or documentation of at least 3 months of failed conservative care; use of fixation implants the policy designates as experimental may also lead to denial.

    • Missing AP and lateral radiograph reports
    • No record of skeletal maturity or age ≥18
    • No documentation of ≥3 months conservative treatment
    • Use of fixation implants listed as experimental/investigational (see policy list)
    Denial Risk

    Cost‑related denial risk for commercial intramedullary implants

    Because commercial intramedullary implants incur substantially higher unit and total costs compared with percutaneous K‑wires, payers may deny coverage for higher‑cost implants if no clinical justification or cost‑effectiveness rationale is provided.

    • Reported unit costs: K‑wire £0.37 vs ToeGrip £236.94 and SmartToe £331 (640–894× increase)
    • Albright et al. found higher total cost for implants and unfavorable incremental cost‑effectiveness
    Documentation requiredRecord of skeletal maturity or explicit statement of age ≥18 in the medical record
    Relevance to coverageSurgical repair is considered medically necessary only in skeletally mature individuals (epiphyseal closure) or those ≥18 years
    Percutaneous K-wire fixation — brief description
    DefinitionTraditional temporary percutaneous Kirschner (K-) wire fixation used to stabilize proximal interphalangeal (PIP) joint arthrodesis during hammertoe correction
    Common usageMost widespread method of surgical stabilization for PIP arthrodesis historically
    Complication profileLower reported hardware failure rates in some series compared with certain intramedullary implants; widely used in comparative studies
    Intramedullary/internal fixation device — examples and summary
    DefinitionCommercial one-piece or multi-component intramedullary/internal implants designed to provide internal fixation for PIP joint fusion without external K-wires (examples: SmartToe, TenFuse, CannuLink, ToeGrip, ToeTac Xpress)
    Examples cited in evidenceSmartToe, TenFuse, CannuLink, ToeGrip, ToeTac Xpress
    Reported outcomesStudies report comparable or slightly higher fusion rates versus K-wires but variable hardware-failure rates (e.g., SmartToe breakage reported) and higher costs
    Implication for coverageThese implants are evaluated individually; some are considered experimental/investigational in the policy due to limited evidence of safety/effectiveness